


Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Dec-2021
Document Type: USP Monographs
DocId: GUID-A3280EF0-1B0F-47BF-BE38-BB84607CA0E8_7_en-US
DOI: https://doi.org/10.31003/USPNF_M44700_07_01
DOI Ref: dy5jy

© 2025 USPC
Do not distribute

Levocarnitine



$C_7H_{15}NO_3$ 161.20

(R)-3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium, inner salt;
(R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium, inner salt CAS RN®: 541-15-1; UNII: 0G389FZZ9M.

DEFINITION

Levocarnitine contains NLT 97.0% and NMT 103.0% of levocarnitine ($C_7H_{15}NO_3$), calculated on the anhydrous basis.

IDENTIFICATION

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): 197K

Analysis: Dry the sample and [USP Levocarnitine RS](#) under vacuum at 50° for 5 h.

Acceptance criteria: Meets the requirements

- B. The retention time of the major peak of the derivatized *Sample solution* corresponds to that of the levocarnitine peak of the derivatized *System suitability solution*, as obtained in the test for *Enantiomeric Purity*.

ASSAY

- **PROCEDURE**

Sample: 100 mg of Levocarnitine

Blank: Mix 3 mL of [formic acid](#) with 50 mL of [glacial acetic acid](#).

Titrimetric system

(See [Titrimetry \(541\)](#).)

Mode: Direct titration

Titrant: [0.1 N perchloric acid](#) VS

Endpoint detection: Visual

Analysis: Dissolve the *Sample* in a mixture of 3 mL of [formic acid](#) and 50 mL of [glacial acetic acid](#). Add 2 drops of [crystal violet TS](#), and titrate with the *Titrant* to an emerald green endpoint. Perform the blank determination.

Calculate the percentage of levocarnitine ($C_7H_{15}NO_3$) in the portion of Levocarnitine taken:

$$\text{Result} = \{[(V_S - V_B) \times N_A \times F] / W\} \times 100$$

V_S = *Titrant* volume consumed by the *Sample* (mL)

V_B = *Titrant* volume consumed by the *Blank* (mL)

N_A = actual normality of the *Titrant* (mEq/mL)

F = equivalency factor, 161.2 mg/mEq

W = *Sample* weight (mg)

Acceptance criteria: 97.0%–103.0% on the anhydrous basis

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.5%

- [CHLORIDE AND SULFATE \(221\), Chloride](#)

Standard solution: 0.50 mL of 0.020 N [hydrochloric acid](#)

Sample: 0.090 g of Levocarnitine

Acceptance criteria: NMT 0.4%

- [ENANTIOMERIC PURITY](#)

Buffer solution: Mix thoroughly 2000 mL of [water](#) with 5 mL of [phosphoric acid](#), and add accurately 13.6 mL of [triethylamine](#) dropwise while stirring.

Solution A: Mix 1500 mL of *Buffer solution* and 500 mL of [acetonitrile](#). Adjust the solution with [phosphoric acid](#) to a pH of 2.6.

Solution B: Acetonitrile

Carbonate buffer solution: Transfer 338 mg of [sodium carbonate](#) and 152 mg of [sodium bicarbonate](#) to a 100-mL volumetric flask, and dissolve in and dilute with [water](#) to volume.

Sodium hydroxide solution: 30% solution of [sodium hydroxide](#) in [water](#)

Acetate buffer solution: Transfer 0.3 mL of [glacial acetic acid](#) to a 100-mL volumetric flask, add 90 mL of [water](#) to dissolve, adjust with [Sodium hydroxide solution](#) to a pH of 4.2, and dilute with [water](#) to volume.

Derivatization reagent: [\(+\)-1-\(9-Fluorenyl\)ethyl chloroformate solution \(\(+\)-FLEC\)](#).

System suitability solution: 1.25 mg/mL of [USP Levocarnitine RS](#) in [water](#)

Sample solution: 1.25 mg/mL of Levocarnitine in [water](#)

Blank: [Water](#)

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: Fluorescence

Excitation wavelength: 260 nm

Emission wavelength: 315 nm

Column: 4.6-mm × 7.5-cm; 2.7-μm packing [L1](#)

Column temperature: 30°

Flow rate: 1.5 mL/min

Injection volume: 20.0 μL

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0.0	100	0
7.4	100	0
7.5	2	98
9.1	2	98
9.3	100	0
11.0	100	0

After each sequence of samples, rinse the column with [water](#) for 10 min and then with [acetonitrile](#) and [water](#) (98:2) for another 10 min.

System suitability

Sample: Derivatized [System suitability solution](#). Prepare as directed in [Analysis](#).

[**NOTE**—The relative retention times for the (+)-FLEC derivatives of *D*-carnitine and *L*-carnitine are about 0.87 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 2.0 between (+)-FLEC derivatives of *D*-carnitine and *L*-carnitine

Analysis

Samples: [System suitability solution](#), [Sample solution](#), and [Blank](#)

Transfer 30.0 μL of the [Blank](#), [System suitability solution](#), and [Sample solution](#) to separate 10-mL test tubes. Add 30 μL of [Carbonate buffer solution](#) and 80 μL of [Derivatization reagent](#) to each test tube and mix by vortex mixer. Allow the solutions to react for 1 h at 45° over a water bath. Cool the test tubes to room temperature, add 5.0 mL of [Acetate buffer solution](#) to each test tube, mix by vortex mixer, and transfer to vials for chromatographic analyses.

Separately inject and analyze equal volumes of derivatized [Blank](#), derivatized [System suitability solution](#), and derivatized [Sample solution](#). Identify the two diastereomer peaks due to (+)-FLEC derivatives of *D*-carnitine and *L*-carnitine from the derivatized [System suitability solution](#) and derivatized [Sample solution](#). Depending on the enantiomeric purity of the [Derivatization reagent](#), these two peaks may contain co-eluting enantiomers of (-)-FLEC derivatives with *D*- and *L*-carnitines, which are accounted in the percentage calculations below. There should be no peaks observed at the retention times of *D*- and *L*-carnitine derivatives from the derivatized [Blank](#).

Calculate the percentage of *L*-carnitine derivative (R_L) from the derivatized [Sample solution](#):

$$\text{Result} = r_L / (r_L + r_D) \times 100$$

r_L = peak response of the *L*-carnitine derivative from the derivatized [Sample solution](#)

r_D = peak response of the *D*-carnitine derivative from the derivatized [Sample solution](#)

Calculate the corrected percentage of L-carnitine ($C_7H_{15}NO_3$) (C_L) in the portion of Levocarnitine taken:

$$\text{Result} = (R_L - P_B)/(P_A - P_B) \times 100$$

R_L = percentage of L-carnitine derivative, calculated previously

P_B = percentage of (-)-FLEC as determined for [\(+\)-1-\(9-Fluorenyl\)ethyl chloroformate solution](#)

P_A = percentage of (+)-FLEC as determined for [\(+\)-1-\(9-Fluorenyl\)ethyl chloroformate solution](#)

Calculate the corrected percentage of D-carnitine in the portion of Levocarnitine taken:

$$\text{Result} = 100 - C_L$$

C_L = corrected percentage of L-carnitine, calculated previously

Acceptance criteria: NMT 0.2% of D-carnitine

• **LIMIT OF POTASSIUM**

[NOTE—The Standard solution and the Sample solutions may be modified, if necessary, to obtain solutions of suitable concentrations adaptable to the linear or working range of the instrument.]

Standard solution: 31.25 µg/mL of potassium in [water](#), prepared from [potassium chloride](#) previously dried at 105° for 2 h

Sample stock solution: 0.625 mg/mL of Levocarnitine in [water](#)

Sample solution A: Transfer 20.0 mL of the Sample stock solution to a 25-mL volumetric flask, and dilute with [water](#) to volume. This solution contains 500 µg/mL of Levocarnitine and 0 µg/mL of added potassium from the Standard solution.

Sample solution B: Transfer 20.0 mL of the Sample stock solution to a 25-mL volumetric flask, add 2.0 mL of the Standard solution, and dilute with [water](#) to volume. This solution contains 500 µg/mL of Levocarnitine and 2.5 µg/mL of added potassium from the Standard solution.

Sample solution C: Transfer 20.0 mL of the Sample stock solution to a 25-mL volumetric flask, add 4.0 mL of the Standard solution, and dilute with [water](#) to volume. This solution contains 500 µg/mL of Levocarnitine and 5.0 µg/mL of added potassium from the Standard solution.

Blank: [Water](#)

Instrumental conditions

(See [Atomic Absorption Spectroscopy \(852\)](#).)

Mode: Atomic absorption spectrophotometry

Analytical wavelength: 766.7 nm

Lamp: Potassium hollow-cathode

Flame: Air–acetylene

Analysis

Samples: Sample solution A, Sample solution B, Sample solution C, and Blank

Determine the absorbances of the solutions against the Blank. Plot the absorbances of the three Sample solutions versus their added potassium concentrations, in µg/mL. Draw the straight line best fitting the three points, and extrapolate the line until it intercepts the concentration axis. From the intercept determine the concentration, in µg/mL, of potassium in Sample solution A.

Calculate the percentage of potassium in the portion of Levocarnitine taken:

$$\text{Result} = (C_K/C_U) \times 100$$

C_K = concentration of potassium in Sample solution A (µg/mL), determined from the intercept of the linear regression line

C_U = concentration of Levocarnitine in Sample solution A (µg/mL)

Acceptance criteria: NMT 0.2%

• **LIMIT OF SODIUM**

[NOTE—The Standard solution and the Sample solutions may be modified, if necessary, to obtain solutions of suitable concentrations adaptable to the linear or working range of the instrument.]

Standard solution: 250 µg/mL of sodium in [water](#), prepared from [sodium chloride](#) previously dried at 105° for 2 h

Sample stock solution: 40.0 mg/mL of Levocarnitine in [water](#)

Sample solution A: Transfer 20.0 mL of the Sample stock solution to a 25-mL volumetric flask, and dilute with [water](#) to volume. This solution contains 32 mg/mL of Levocarnitine and 0 µg/mL of added sodium from the Standard solution.

Sample solution B: Transfer 20.0 mL of the Sample stock solution to a 25-mL volumetric flask, add 2.0 mL of the Standard solution, and dilute with [water](#) to volume. This solution contains 32 mg/mL of Levocarnitine and 20 µg/mL of added sodium from the Standard solution.

Sample solution C: Transfer 20.0 mL of the Sample stock solution to a 25-mL volumetric flask, add 4.0 mL of the Standard solution, and dilute with [water](#) to volume. This solution contains 32 mg/mL of Levocarnitine and 40 µg/mL of added sodium from the Standard solution.

Blank: [Water](#)

Instrumental conditions

(See [Atomic Absorption Spectroscopy \(852\)](#).)

Mode: Atomic absorption spectrophotometry

Analytical wavelength: 589.0 nm**Lamp:** Sodium hollow-cathode**Flame:** Air-acetylene**Analysis****Samples:** *Sample solution A, Sample solution B, Sample solution C, and Blank*

Determine the absorbances of the solutions against the *Blank*. Plot the absorbances of the three *Sample solutions* versus their added sodium concentrations, in $\mu\text{g/mL}$. Draw the straight line best fitting the three points, and extrapolate the line until it intercepts the concentration axis. From the intercept determine the concentration, in $\mu\text{g/mL}$, of sodium in *Sample solution A*.

Calculate the percentage of sodium in the portion of Levocarnitine taken:

$$\text{Result} = (C_{\text{Na}}/C_U) \times 100$$

C_{Na} = concentration of sodium in *Sample solution A* ($\mu\text{g/mL}$), determined from the intercept of the linear regression line

C_U = concentration of Levocarnitine in *Sample solution A* ($\mu\text{g/mL}$)

Acceptance criteria: NMT 0.1%**SPECIFIC TESTS**

- [pH \(791\)](#)

Sample solution: 50 mg/mL**Acceptance criteria:** 5.5–9.5**Change to read:**

- [WATER DETERMINATION \(921\)](#)▲, *Method I, Method Ia*▲ (USP 1-Dec-2021) : NMT 4.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers at temperatures between -15° and 35° . Protect from light.

- [USP REFERENCE STANDARDS \(11\)](#)

[USP Levocarnitine RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
LEVOCARNITINE	Fatkhulla K Tadjimukhamedov Associate Scientific Liaison	NBDS2020 Non-botanical Dietary Supplements

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 49(2)

Current DocID: GUID-A3280EF0-1B0F-47BF-BE38-BB84607CA0E8_7_en-US**DOI:** https://doi.org/10.31003/USPNF_M44700_07_01**DOI ref:** [dy5jy](#)